A. Septic arthritis
     1. Pathogens
  • S. aureus
  • Beta hemolytic strep
  • Neisseria gonorrhoeae
  • E. coli
  • Other enterobacteriaceae
  • Pseudomonas aeruginosa
  • Kingella kingae
     2. Aquisition: direct inoculation (trauma), hematogenous spread (bacteremia)
  •      risk factors: RA, other joint pathology
     3. Dx: 
  • DDx: RA, gout, pseudogout, reactive arthritis (all cause PMNs in joint fluid), viral arthritis, lyme dz
  •      clinical: joint pain, swelling, decreased ROM
    • large joints more common, may be polyarticular (20% cases)
  • Always send BCx
  • Normal ESR, CRP, WBC d/n exclude Dx
  • Consider checking GC / Chlamydia
  • Joint aspirate: send for cell count, gram stain & culture, crystal exam
    • > 50k mm^3 WBC (neutrophilic) is cutoff
    • >100k is highly suggestive of infection
    • pos. gram stain/culture
    • low glucose (<40mg/dL)
    • usually no crystals
  • Native vs. Prosthetic Joint
    • ***
     4. Tx:
  •      Empiric: 
    • cover for: 
      • S. aureus, incl. MRSA
        • consider risk factors for MRSA
      • base further therapy on gram stain
    • ABx: 
      • vancomycin; plus
      • ceftrazidime, cefepime, or zosyn

Meningitis

Bacterial
  • Strep Pneumo
  • Meningococcal
    • G- diplococci
    • Clinical: sore throat, HA, drowsiness, fever, neck stiffness, photophobia , hemorrhagic skin rash with septicemia
  • H. influenza (infants, young children)
  • Listeria monocytogenes
  • E. coli, Group B strep
  • TB
    • Clinical: always focus of infx outside CNS, but 25% without signs/symptoms. Usually gradual onset, though occasionally rapid and presents like SAH
Treatment of Bacterial Meningitis
  • Community Acquired
    • Vanco (for resistant pneumococcus), plus
    • Ceftriaxone 2g or cefotaxime, or
    • Ampicillin (age > 50) +/- gentamicin for synergy (certainly add if bacteremia / sepsis) & monitor drug levels (peak and trough) & monitor for toxicity (ototoxicity, nephrotoxicity)
    • Dexamethasone 10mg IVq6h x4d
    • Rifampin prophy for close contacts of pt with meningococcal meningitis; cipro prophy for adult contacts?
  • Immunocompromised
    • Ceftriaxone 2g IV q12h or cefotaxime or cefepime (if pseudomonas risk); plus
    • Vanco; plus
    • Ampicillin 2.0g IV q4h
    • Steroids clearly indicated for Strep pneumo; some would give for all bacterial meningitis
  • Pen Allergy
    • Chloramphenicol (covers meningococcus, H. influenza, S. pneumo, E. coli
  • Duration of Treatment
  • Practice Guidelines for Bacterial Meningitis • CID 2004:39 (1 November) • 1281
     Microorganism : Duration of therapy, days
  • Neisseria meningitidis :  7
    Haemophilus influenzae : 7
    Streptococcus pneumoniae : 10–14
    Streptococcus agalactiae : 14–21
    Aerobic gram-negative bacilli : 21
    Listeria monocytogenes : 21

Viral Meningitis 
  • Overview: The most common meningitis
  • Viruses
    • HSV, mumps, lyphocytic choriomeningitis, polio, coxsackie, echo, japanese encephalitis, eatern and western equine, louping ill, HIV
    • Dx: PCR
    • Generally speaking, benign course with complete recovery

Fungal Meningitis
  • Cryptococcus neoformans
  • Coccidioides immitis
Protozoal Meningitis
  • Naegleria
    • stagnant fresh water, inhaled --> meninges
    • healthy, non-immunosuppressed patient
  • Acanthamoeba spp.
    • cause chronic granulomatous amebic encephalitis

Encephalitis
  • Overview: Usually viral, though infectious agent often not identified. Brain parenchyma inflammed in encephalitis, as oppossed to the lining of the brain in meningitis. 
  • Clinical: AMS, szr, depressed consciousness, nausea, vomiting, fever
  • Most common cause: HSV
  • Causative agents
    • Viruses
      • HSV
      • VZV
      • CMV
      • HIV
      • West Nile
      • Mumps
      • Rabies
      • Louping ill
      • Polio, other enteroviruses
      • Eastern and western equine encephalitis
      • St. Louis encephalitis
      • Japanese encephalitis
      • Californian encephalitis
      • Rubella
      • Measles
      • JC virus
    • Prion
      • CJD
    • Protozoa and fungi
      • toxo
      • crypto
      • plasmodium falciparum
      • Trypanosoma spp.
    • Bacteria
      • Treponema pallidium
      • Mycoplasma pneumoniae
      • Borrelia burgdorferi
  • Treatment
    • HSV
      • Acyclovir IV x21d
    • Rabies
      • Following a bite wound:
        • clean the wound, debride
        • Confirm if animal had rabies
        • Give human rabies immunoglobulin
          • give half IM and half directly into the wound
        • Active immunization with killed virus
    • Other
      • supportive
  • West Nile Virus
    • Clinical: encephalitis
    • Dx: viral RNA or IgM in serum or CSF
    • Tx: supportive
Brain Abscess
  • Overview: look for predisposing factor (surgery, trauma, chronic osteomyelitis of adjacent bone, septic empbolism, chronic cerebral anoxia). Acute abscesses generally mixed oropharyngeal flora; chronic more typically TB or C. neoformans. If immunosuppressed, consider fungi, protozoa
  • Causes
    • Bacterial: TB, syphilis, Brucellosis, Lyme, Nocardia, Actinomycosis
    • Fungal: Crypto, Coccidio, Histo, Candida, Blasto
    • Parasitis: Toxo, cysticercosis
  • Dx: 
    • CT or MRI 
    • Gold standard = surgical drainage with gram stain & culture
    •  Note: LP is contraindicated!
  • Tx: surgical drainage if abscess well encapsulated. ABx 1-2 months IV ABx; give longer course especially if not surgically drained. 
    • Treat at minimum until there is documented radiologic improvement
    • Consider treatment until complete radiologic resolution
    • Mean time to radiologic resolution is 4 months, but may take up to one year for MRI enhancement to resolve
  • Recurrence rate: ~ 8 %

CNS Disease Caused by Parasites
  • Toxoplasma gondii
  • Cerebral malaria
  • Toxocara cati and Toxocara canis
  • Echinococcus granulosus
    • sheep
    • hydatid cysts (liver, lungs, brain, kideny, muscle)
  • Cysticercosis
    • Taenia solium, human tapeworm
Tetanus and Botulism
  • Overview: Bacteria that release toxins which act on the CNS
  • Tetanus
    • toxin carried by peripheral nerves to the CNS, bines neurons, blocks release of inhibitory molecules in the synapse --> unopposed muscle activation
    • Clinical: hyperreflexia, muscle rigidity, uncontrolled muscle spasms, lockjaw (contraction of jaw muscle), dysphagia, neck stiffness, eventual respiratory failure
    • Dx: clinical
    • Tx: human antitetanus immunoglobulin
      • wound care, debridement, penicillin
  • Botulism
    • Cl botulinum toxin blocks acetylcholine release from peripheral nerves --> paralysis
    • Clinical: weakness and paralysis, which is descending. Dysphagia, diplopia, vomiting, vertigo, respiratory failure.
    • Dx: clinical
    • Tx: trivalent antitoxin

Myelopathy / Myelitis
  • :: inflammation of the spinal cord itself
  • Clinical: motor weakness, sensory loss
  • Anterior horn cells may be infected by polio, coxsackie, enterovirus 71, West Nile Virus
  • Herpes family viruses can cause acute myelitis

Acute Hemorrhagic Leukoencephalopathy
  •  Infection triggers an autoimmune response which results in perivascular demyelination and hemorrhage in the brain parenchyma
    •  hyperacute form of acute disseminated encephalomyelitis (ADEM), characterized by vascular necrosis and demyelination
  • Clinical: fever, headache, rapid progression to coma; death typically within one week
  • May follow viral infection, drug exposure, or vaccination  
    • Influenza A
    • Varicella
    • Measles




Orbital Cellulitis


Fungal Sinusitis / Rhino-Orbital-Cerebral Infection
A. Mucormycosis previously known as Zygomycosis (infx with organisms from Muroomycotina group: e.g. Rhizopus oryzae, Mucor, etc.)
  • Treatment:
    • Amphotericin B, lipid formulation, 5mg/kg
    • Superior Alternative?: Amphotericin B + Caspofungin (not standard of care)
      • (see Clin Infect Dis. 2008 August 1; 47(3): 364–371. doi:10.1086/589857)
    • 2nd line: Posaconazole
  • Complications: CNS involvement
  • Risk factors: DM2, neutropenia, immunosuppression

Otitis Media (OM)
  • Acute OM
    • S. pneumo, H. influenzae, Moraxella catarrhalis
  • Chronic OM
    • Aerobes
      • Pseudomonas aeruginosa, Staph. aureus, Proteus spp.
    • Anaerobes
      • Bacteroides, peptococcus or petostreptococcus, and Propionibacterium acnes
    • Fungi
      • aspergillus, candida spp.
  • Case Study
    • Chronic OM complicated by mastoiditis, meningitis, and bacteremia
    • DDx: acquired cholesteatoma, congenital cholesteatoma, granulation tissue without a cholesteatoma. Presence of any of these conditions may --> intracranial and extracranial complications  with chronic OM. Compx: extradural abscess, subperiosteal abscess, meningitis, venous sinus thrombosis, thrombphlebitis --> brain abscess
      • cholesteatoma:: cystlike mass of squamous epithelial debris in the middle ear
        • acquired may result from chornic infx (& retraction of TM)
        • congenital may  arises from epidermoid rest in developing middle ear
    • Tx: ABx, neurosurg consult
      • Neurosurg
        • sterotactic drainage of empyema
        • epidural abscess can be drained through burr hole
        • subdural empyema requires craniotomy
        • ventriculostomy or permanent shunt for hydrocephalus
      • Otologic Mgmt
        • R. mastoidectomy and decompression of sigmoid sinus to decresae infectious load and drain Bezold's abscess
        • anticoagulation for sigmoid sinus thrombus (only if it extends beyond sigmoid, or if neuro changes or persisent fever)
        • L. mastoidectomy
      • ID Mgmt



     A. CAP
  • Pathogens
    • Strep pneumo
    • H. influenzae
    • Moraxella catarrhalis
    • Chlamydophila pneumiae
    • Legionella spp.
    • Mycoplasma pneumoniae
    • Viral: influeza, RSV, parainfluenza, adenovirua 14, metapneumovirus
  • Clinical
    • Hx: cough, fever, sputum production, dypsnea +/- pleurisy or GI symptoms
    • Physical exam: fever, tachypnea, rales, or evidence of consolidation
    • Site of care: if score 0-1, may treat as outpatient
      • Consciousness decreased
      • Urea, blood increased
      • Respiratory rate >30
      • Blood pressure < 90
      • 65 (age)
  • Dx:
    • CXR
      • bacteria: consolidation
      • viral: b/l and interstitial
    • Dx tests for major pathogens
      • S. pneumo: BCx, sputum G stain and Cx, urine antigen assay
      • Legionella: urine Ag assay and Cx on selective media
      • C. pneumoniae: no tests; rare cause of CAP
      • M. pneumoniae: IgM, peds only
      • S. aureua, Moraxella catarrhalis, H. influenzae, other GNB: blod Cx, sputum G stain and Cx
      • Viral: PCR
  • Tx:
    • Outpatient 
      • empiric:
        • Azithromycin (500mg PO d1, then 250mg d2-5 = Zpak); or
        • Clarithromycin 1g (XR) po daily or 500mg po BID x 7d
      • with comorbidity (COPD, DM, CHF, etc), or recent ABx
        • as above; or
        • Moxifloxacin 400mg po daily x 7d; or
        • Levofloxacin 750mg po daily x 5d
    • Hospitalized
      • Non-ICU
        • Empiric:
          • 1. FQ alone
            • Moxifloxacin 400mg po/iv daily x 7-10d; or
            • Levofloxacin 750mg po/iv daily x 7-10d
          • 2. Cephalosporin + macrolide
            • Ceftriaxone 1g IV q24hr OR Fefotaxime 1g iv q8hr + azithro 500mg IV/PO daily
        • Aspiration:
          • 1. Clindamycin 600mg IV q8hr + FQ
          • 2. Augmentin
          • 3. Zosyn
        • Influenza with bacterial superinfection (S. pneumo > S. aureus > GAS)
          • Ceftraixone or cefotaxime +/- oseltamivir 75 mg po BID x 5 d
          • consider MRSA, add Vanc or Linezolid
        • If structural lung dz, consider covering for Pseudomonas
      • ICU, empiric
        • ***
     B. HAP
  • Pathogens
    • Staph. aureus (MRSA > MSSA)
    • G- bacilli: Klebsiella, Enterobacter, E. coli, Pseudomonas, S. maltophilia, Acietobacter spp., and others
    • Dreaded: KPC
    • Legionella spp.
    • Anaerobes (aspiration)
    • Viruses: influena, RSV, parainfluenza
  • Clinical
    • Symptoms > 48 hours after hospitalization
      • early: occurs w/in 4d hospitaliztion
      • Late-onset: > 4d, usually more resistant pathogens
    • Organisms you can IGNORE:
      • Staph epi
      • Eterococcus spp.
      • ALL G+ rods other than Nocardia and B. anthracis, Candida spp.
    • Biggest problems to treat: P. aeruginoas, Acinetobacter spp.
  • Diagnosis
    • Cx: blood, expectorated sputum, +/- BAL
    • Viral studies (influenza, RSV, etc.)
    • Legionella Ag
    • DDx: CHF, PE, drug fever, ARDS, inflammatory lung dz, malignancy
  • Tx:
    • EMPIRIC
      • knowledge of local antibiogram helpful
      • Risk of MDR pathogen: hospitalized > 4d, admitted from chronic care facility, ABx received w/in past 90 d, immunosuppression, high rates of ABx resistance in region or facility
      • Low Risk of MDR (early HAP)
        • Ceftriaxone 2 g IV
        • Levofloxacin 750mg IV/PO
        • Ciprofloxacin 400mg q8hr IV
        • Moxifloxacin 400mg q24hr IV
        • Amp/sulbactam 2gm IV q6h
        • Ertapenem 1gm IV q24hr
      • High Risk of MDR: empiric Tx should cover P. aeruginosa, other GNB (e.g. ESBLs, KPC producing Dklebsiella or other GNs, Acinetobacter, etc), S. aureus (MRSA)
        • Use (1) beta-lactam and (2) FQ or aminoglycoside and (3) vanc or linezolid
        • if high concern for ESBL, use carbapenem
        • (1) Anti-pseudomonal beta-lactams (IV, choose one)
          • Cefepime 1-2gm IV q8-12hr
          • Ceftazidime 2gm IV q8h
          • Imipenem 0.5-1.0g IV q6hr
          • Meropenem 1gm IV q8h
          • Zosyn 4.5g IV q6hr
        • PLUS (2) one of the following:
          • Levofloxacin 750 mg IV q24h
          • Ciprofloxacin 400mg IV q8h
          • Gentamicin 7mg/kg/d IV
          • Tobramycin 7mg/kg/d IV
          • Amikacin 20mg/kg/d IV
          • note: goal trough aminoglycoside levels: gentamicin/tobramycin <1microg/mL, amikacin < 4-5microg/mL
        • PLUS (3) MRSA coverage:
          • Vancomycin 15mg/kg IV q12h (trough > 15-20)
          • Linezolid 600mg IV q12h
      • F/U @ 48-72h (clinically improved): pretreatment culture(s) negative, consider stopping ABx. If Cx pos., de-escalate regiment to specific pathogen, treat for 7-8d
      • F/U @ 48-72hr (clinically unimproved): if Cx neg., look for alternative causes. If Cx pos., adjust ABx accordingly
      • Narrow drug choice based on susceptibility when available
      • Duration: 8d. Some treat longer for S. aureus or P. aeruginosa


Cellulits/Erysipelas
  • Pathogens
    • Strep spp., usually group A
    • Staph aureus, MRSA now most common in and out of hospital
    • Neutropenia: Pseudomonas, other GNB
  • Clinical
    • Erysipelas: superficial, sharply demarcated: nearly always group A streptococcus
    • Cellulitis: deeper (subcu). Also usually group A strep
    • exam: red, hot, tender skin +/- fever & adenopathy
    • DDx: allergy, gout, zoster, erythroderma, insect bite, panniculitis, Lyme dz, Sweet's syndrome, pyoderma, fixed drug rxn, thrombophlebitis, nec fasc, pyomyositis, DVT
  • Dx
    • largely a clinical Dx
  • Tx
    • Outpt
      • Strep - ONLY consider if clearly erysipelas
        • Amoxicillin 500500mg po tid x 7-10d
        • Cephalexin 500mg po qid x7-10d
      • Cellulitis (generally want to cover strep, but also Staph)
        • Cephalexin 500mg po qid x7-10d
        • Clindamycin 150-300mg tid or qid po
          • Covers Strep, MSSA, and MRSA
        • Augmentin 500mg tid or 875mg bid x 7-10d
          • Covers Strep and MSSA
      • MRSA (community acquired) - consider if cellulitis with purulent focus
        • TMP/SMX 1-2 DS po bid (note: poor Strep coverage w/ bactrim, may need to combine w/ cephalexin)
        • Clindamycin 300 - 450mg po tid
        • Doxycycline 100mg po bid
        • Linezolid 600mg po bid
      • Beta-lactam allergy
        • Azithro 500mg po x1 day, then 250mg po daily x 4 days
        • Clarithromycin 250mg po BID x 7-10d
        • Clindamycin 300mg po tid x 7-10d
    • Inpt
      • Strep and S. aureus (presume MRSA)
        • Clinda (if D test neg) 600mg IV q8hr
        • Vanc 15mg/kg IV q12hr
        • Linezolid 600mg IV q12hr
        • Daptomycin 4mg/kg IV q24h
        • Ceftaroline 600mg IV q12hr
        • Telavancin 10mg/kg IV once daily (infuse over 1 hr)
      • Strep only (e.g. erysipelas)
        • Cefazolin 0.5 - 1.5g IV q8h
        • Cefotaxime 1-2gm IV q8h
        • Ceftriaxone 1-2g IV q24h
        • Clinda 600mg q8h IV or 300mg PO qid
      • Beta-lactam allergy
        • Clinda
        • Vanc
    • Adjunctive Tx
      • elevation of affected site
      • treat associated conditions
    • Prevention
      • prevent edema: diuretics, limb elevation, compression stockings, decongestive therapy
      • keep skin hydrated with emollients
      • treat dermatophytic infections, esp. interdigital spaced on feet

V. Febrile Neutropenia
A. Overview
  • Common in BMTU, cancer patients 2/2 meylosuppression
  • halflife of PMN = 6-8h
    • Thus Nphils affected first, then plt (1/2 life 7d), then RBC (1/2 life 120d)
  • Less than 50% febrile neutropenic pts will have established infx
  • ~ 1/5 pts w/ ANC < 100 will have bacteremia
  • Si & Sy of typical bacterial infx (induration, erythema, pustulation, CXR infiltrates, CSF pleocytosis) may be absent in pts w/ neutropenia
  • Median time to defervescence in treated pt: 5d (range 2-7d)
    • Do NOT modify initial ABx choice unless clinical deterioration or new data dictate change
  • Sinusitis should be aggressively managed, as there is risk for invasive mold infx
  • Risk factors for poor outcome in febrile neutropenia
    • symptomatic
    • hypotension
    • COPD
    • Hx prior fungal infx
    • dehydration
    • inpt status (vs. outpt)
    • age > 60
    • duration of Npenia (esp. > 7d)
B. Definition
  • fever: single oral temp > 38.3 (101 F) or temp > 38 sustained for 1 hour; AND
  • Neutropenia: ANC < 500 cells/mm3 OR ANC predicted to fall below this in 48h
C. Pathogens
  • Bacterial
    • G+
      • CoNS
      • S. aureus (including MRSA)
      • Enterococcus spp. (including VRE)
      • Viridans strep (esp. in pt with malignancy/mucositis)
      • Strep. pneumo
      • Stre. pyogenes
      • G+ bacilli: Corynebacterium jeikeium, Bacillus spp., Propionibacterium spp.
    • G-
      • Enterobacteriaceae: E. coli, Klebsiella spp., Enterobacter spp.
        • consider ESBL, KPC
      • Pseudomonas spp.
      • Citrobacter spp.
      • Acinetobacter spp.
      • Stenotrophomonas maltophilia
    • Anaerobes
      • less common
      • periodontal or perirectal abscess
      • intra-abdominal infx
  • Fungal
    • Candida spp.
      • including fluconazole-resistant strains
      • Aspergillus spp.
      • Other filamentous fungi
        • e.g. Fusarium spp.
D. Mgmt / ABx Discussion

Initial Choice of ABx
  • First line: single agents
    • Meropenem
      • Carbapenems:
        • beta lactam
        • broad spectrum against aerobic and anaerobic G+ and G- organisms
          • Strep
          • MSSA
            Neisseria spp.
          • Haemophilus spp.
          • Anaerobes
          • Aerobic G-, including
            • Pseudomonas
        • Resistant Organisms
          • Stenotrophomonas maltophilia
        • bactericidal (except against enterococci)
        • Imi vs. Mero: 
          • Meropenem somewaht better against G-
          • Imi somewhat better against G+ cocci
    • Imipenem-cilastatin
    • Cefepime
      • approved for use as single agent
      • avoid if high ESBL prevalence
    • Pen Allergic?
      • Aztreonam + Vanc
        • Monobactams
          • G- coverage only, the drug does not have affinity for penicillin binding proteins
          • spectrum is similar to that of aminoglycosides, but it is not nephrotoxic
      • Cipro + clinda
  • Add Vanc?
    • Not recommended for initial Tx of febrile neutropenia
    • Consider in pt with chronic indwelling catheters or known MRSA+
    • suspected skin or soft-tissue infx
    • PNA
    • hemodynamic instability
    • Vancomycin
      • The Glycopeptides
        • Vanc is bactericidal (except against enterococci)
        • Vanc + Gent is synergistic against S. aureus and enterocci, because vanc increases permeability of the cytoplasmic membrane
  • Alternatives to Vanc
    • Linezolid
      • be aware of bone marrow suppression
      • The Oxazolidinones:
        • Linezolid became available in 2000 for treatment of VRE, and resp. & skin infx caused by G+ bacteria
        • Bacteriostatic against enterococci and staph
        • Also active against:
          • Legionella spp.
          • Chlamydia pneumoniae
          • H. influenzae
    • Daptomycin
      • The Lipopeptides
        • Dapto became available in 2004 for treatment of complicated skin and soft tissue infections
        • In contrast to linezolid, it is bactericidal
          • Studies so far have shown that linezolid and dapto are equally effective in treatment of VRE in BMTU patient population
        • Spectrum of Activity:
          • Broad range of activity against G+ organisms
  • Anti-fungal
    • Vori
      • active against aspergillosis, Scedosporium apiospermum, and Fusarium spp.
    • Caspofungin
      • FDA approved for use in febrile neutropenia
      • Active against Candida spp. & Aspergillus
    • Micafungin
      • alternative to caspo
      • not FDA approved, only small studies
    • Fluconazole
      • C. albicans & non-albicans spp. 
      • avoid for routine empiric fungal coverage, as many pts have been exposed to azoles before
    • Ampho B
      • FDA approved for use in febrile neutropenia
  • KPC
    • polymyxin-colistin
    • tigecycline
  • Low Risk Pt
    • Augmentin + Cipro
When and How to Modify ABx
  • Modify based on: Suspected source of infx, culture data, sensitivity data
  • Persistent fever: RARELY requires empiric changeto initial ABx choice
  • If you chose to add vanc:
    • it may be stopped after 2 DAYS if no evidence G+ infx
  • Pt persistently hemodynamically unstable:
    • Broaden to include G+ coverage
    • Coverage of resistant organisms
    • Anaerobic coverage
    • Fungal coverage
  • Persistent fever after 4-7 days, & no identified source of infx
    • Add fungal coverage
      • note: fungal infx usually occurs after 7d of neutropenia
      • If pt already on anti-fungal prophylaxis, then consider switch to different class of anti-fungal in IV form
How Long Should Empiric ABx be Given?
  • Continue for duration of neutropenia, or longer if clinically necessary
  • if all signs/symptoms resolved & pt still Npenic, can resume oral FQ prophylaxis until marrow recover
V. Transplant Infections
A. Overview
B. Infections by transplant type
     1. Bone Marrow Transplant
          A. Auto
          B. Allo

Lower UTI
  • Aerococcus
    • Aerococcus urinae
      • Pre-MALDI-TOF: A. urinae difficult to detect, often confused with Strep. or Staph. spp. 
        • Urinary specimen: will appear to be alpha hemolytic strep, based on appearance of blood agar plate
          • in this case, would be regarded as a contaminant
        • Blood specimen: will appear to be Staph. spp. based on microscopic appearance
      • Post-MALDI: we now have a rapid, accurate way to detect Aerococcus spp.
    • Management of aerococcus infections
      • Aerococcus urinae and Aerococcus sanguinicola common causes of UTI and invasive infections, especially IE
    • Antibiotics and Resistancc, Aerococcus spp.
      • General:
        • Sensitive to penicillins, cephalosporins, carbapenems, vanc
      • UTI
        • Aerococcus urinae
          • Thought to have significant resistance to: TMP-SMX, ciprofloxacin
      • IE
        • beta-lactam + aminoglycoside
      • Peritonitis in patients on PD or w/ ascites
    • Predisposing factors: Underlying systemic or urologic disease (e.g. bladder diverticuli, DM2)
    • Virulence factors: largely unknown